Antimicrobial peptide AMP-17 induces protection against systemic candidiasis and interacts synergistically with fluconazole against

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

4 citing papers in PubMed.

1. Combination antifungal therapy against resistant C. albicans: efficacy and immune response in mice.AMB Express · 2026
   Article
2. Harnessing random peptide mixtures to combat multidrug-resistant fungal infections.mBio · 2026
   Article
3. Integrative computational-experimental discovery and translation of antifungal peptides for multidrug-resistant fungi.Frontiers in microbiology · 2026
   Review
4. The dual antifungal and antibiofilm activities of β-carotene against multidrug-resistant Candida albicans induce wound healing in a diabetic rat model: an in vitro and in vivo study.BMC microbiology · 2025
   Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

8 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as